David Westenberg's questions to Fulgent Genetics Inc (FLGT) leadership • Q1 2025
Question
David Westenberg asked about the expected adoption cadence for the therapeutic candidate FID-007, the potential for using capital to expand sales and marketing, and the drivers behind the strong BioPharma Services performance.
Answer
CEO Ming Hsieh explained that FID-007 targets head and neck cancer initially with potential for broader applications. CFO Paul Kim and CCO Brandon Perthuis confirmed a planned ramp-up in sales and marketing spend from $7.6M in Q1 to a projected $10M-$11M per quarter for the rest of the year to fund new hires. Brandon Perthuis attributed BioPharma's strength to expanded service capabilities, which address a larger market and deepen client relationships, while noting the business remains variable quarter-to-quarter.